Heart Failure Biomarkers

Launched by I.R.C.C.S OSPEDALE GALEAZZI-SANT'AMBROGIO · Sep 24, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Heart Failure Biomarkers," is studying how inflammation in the body relates to heart failure, a condition where the heart struggles to pump blood effectively. Specifically, researchers are looking at a marker known as the fibrin/albumin (FAR) ratio to see if it can help predict health outcomes for patients with heart failure. The trial will include adult participants aged 18 and older who either have just been diagnosed with heart failure or are already receiving treatment. Eligible participants may have a specific type of heart failure known as reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), and they can also have a condition called atrial fibrillation, which affects heart rhythm.

If you or a loved one is considering participating, it’s important to know that participants will need to sign consent to join the study. However, individuals with certain health issues, such as infections, autoimmune diseases, or severe kidney and liver conditions, cannot take part. Pregnant or breastfeeding women also cannot participate. The trial is not yet recruiting, so there’s no immediate action needed, but it represents a significant step in understanding heart failure and how inflammation impacts it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years
• • Patients with newly diagnosed or already treated heart failure (NYHA class II-IV) with HFrEF and HFpEF with and without atrial fibrillation.
• • Patients who sign the consent to participate in the study
• Exclusion Criteria:
• • Patients with infectious/autoimmune diseases, neoplasms, liver failure, renal failure (Cl creatinine \< 30 mL/L), structural cardiomyopathies and pericarditis.
• • Pregnant/breastfeeding women (verified by self-declaration)